![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, February 14, 2013 11:45:10 AM
http://finance.yahoo.com/news/timing-rebound-dynavax-155919193.html
By David Russell (david.russell@optionmonster.com)
Feb 14, 2013, 11:43AM EST
One investor is looking for Dynavax Technologies to come back from a brutal selloff last year.
optionMONSTER's Heat Seeker monitoring program detected the purchase of 2,000 July 4 calls for $0.75 and the sale of an equal number of March 6 calls for $0.12. Volume was below open interest in the 6s, so there are two possible explanations of the activity.
One is that an existing position was rolled down in price and further out in time. That gives the investor a greater chance to profit, but for an additional cost of $0.63.
The more likely possibility is that both trades were opened as part of a bullish diagonal spread. In that case, the investor has locked in a purchase price of $4 through the summer while agreeing to sell the stock for $6 if it goes above that level during the next month.
In this case, should DVAX remain below $6 through March expiration, the trader can sell more calls at the higher strike to further reduce the cost basis. (See our Education section for more on how options can be used to manage trades.)
DVAX is down 0.25 percent to $3.21 in morning trading. It lost almost half its value on Nov. 16 after a Food and Drug Administration advisory panel voted against approval of its Heplisav hepatitis B vaccine. Since that drop, however, the shares have been trying to rebound.
Total option volume is twice the daily average so far in the session, with calls outnumbering puts by 51 to 1.
All that is needed to make a happy life is within yourself, in your way of thinking. -Marcus Aurelius
Recent DVAX News
- Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program • PR Newswire (US) • 06/27/2024 08:09:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 09:37:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 12:32:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 12:30:49 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 12:28:17 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 12:26:33 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 12:23:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 12:21:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 12:19:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 12:18:05 AM
- Dynavax to Present at Upcoming Investor Conferences • PR Newswire (US) • 05/28/2024 08:18:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:05:18 PM
- Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S. • PR Newswire (US) • 05/14/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:10:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:05:25 PM
- Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates • PR Newswire (US) • 05/08/2024 08:01:00 PM
- Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 • PR Newswire (US) • 04/24/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:25:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/02/2024 01:17:21 AM
- Dynavax to Present at TD Cowen's 44th Annual Health Care Conference • PR Newswire (US) • 02/27/2024 11:54:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/22/2024 09:10:48 PM
- Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance • PR Newswire (US) • 02/22/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 11:36:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:45:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:44:37 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM